Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$15.55
-0.41 (-2.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-175.3M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.8%
↓Gross Margin
73.4%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-17.3%
FCF CAGR
—
FCF margin
-29.0%
FCF / Net income
0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $605.1M · net income $-262.6M · FCF $-175.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $605.1M | $605.1M | $1.23B | $1.82B | $1.07B |
| Net Income | $-262.6M | $-262.6M | $232.1M | $501.0M | $181.5M |
| EBITDA | $-197.0M | $-197.0M | $361.5M | $656.4M | $268.6M |
| EPS | -0.64 | -0.64 | 0.56 | 1.21 | 0.44 |
| Gross Margin | 73.4% | 73.4% | 85.4% | 90.2% | 87.2% |
| Operating Margin | -35.8% | -35.8% | 24.5% | 34.7% | 22.5% |
| Net Margin | -43.4% | -43.4% | 18.9% | 27.5% | 16.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.02 | 0.01 | — |
| Current Ratio | 1.28 | 1.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-175.3M | $-175.3M | $-135.9M | $-215.5M | $-250.9M |
| Returns | |||||
| ROE | -6.8% | -6.8% | 5.5% | 12.5% | 5.1% |
| Valuation | |||||
| P/E | — | — | 42.25 | 44.02 | 153.25 |
| EV/EBITDA | — | — | 26.46 | 32.95 | 100.34 |
| P/B | 1.66 | 1.66 | 2.32 | 5.49 | 7.82 |
| Growth & Yield | |||||
| Revenue Growth | -50.8% | -50.8% | -32.6% | 70.3% | — |
| EPS Growth | -214.3% | -214.3% | -53.7% | 175.0% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.56 → -0.64
Residual
-27.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.